Methylphenidate Hydrochloride Extended Release Tablet
NDC Package 10702-075-06
Package Information
Methylphenidate Hydrochloride Extended Release tablets is methylphenidate hydrochloride extended-release tablets are indicated for the treatment of:• Attention Deficit Hyperactivity Disorders (ADHD) in pediatric patients 6 years and older and adults • Narcolepsy. This formulation utilizes a tablet delivery system. Marketed by Kvk-tech, Inc., this product is identified by NDC 10702-075 and is authorized under FDA application ANDA207488.
Identification & Billing
- RxCUI: 1091145 - methylphenidate HCl 10 MG 8HR Extended Release Oral Tablet
- RxCUI: 1091145 - 8 HR methylphenidate hydrochloride 10 MG Extended Release Oral Tablet
- RxCUI: 1091145 - methylphenidate HCl 10 MG 8 HR Extended Release Oral Tablet
- RxCUI: 1091225 - methylphenidate HCl 20 MG 8HR Extended Release Oral Tablet
- RxCUI: 1091225 - 8 HR methylphenidate hydrochloride 20 MG Extended Release Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 10702 - Kvk-tech, Inc.
- 10702-075 - Methylphenidate Hydrochloride Extended Release
- 10702-075-06 - 60 TABLET in 1 BOTTLE
- 10702-075 - Methylphenidate Hydrochloride Extended Release
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (10702-075). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 10702-075-06 identifies a specific commercial package of 60 tablet in 1 bottle of Methylphenidate Hydrochloride Extended Release, a human prescription drug labeled by Kvk-tech, Inc.. This tablet is formulated for oral use and contains methylphenidate hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Kvk-tech, Inc. on June 09, 2015. The current certification is valid through December 31, 2026.
How is this Kvk-tech, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 10702007506. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.